These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Adenosine receptor blockade enhances isoproterenol-induced increases in cardiac interstitial adenosine. Author: Heller LJ, Dole WP, Mohrman DE. Journal: J Mol Cell Cardiol; 1991 Aug; 23(8):887-98. PubMed ID: 1942090. Abstract: The failure of adenosine receptor antagonists to consistently attenuate metabolic coronary vasodilation suggests that adenosine is not a primary regulator of functional hyperemia. An alternative hypothesis, however, is that metabolic stimulation of the heart in the presence of an adenosine receptor antagonist results in enhanced interstitial levels of adenosine which then might overcome the blockade. To test this hypothesis, interstitial levels of adenosine and inosine were estimated by HPLC analysis of fluid which exudes from the epicardial surface of isolated rat hearts perfused with crystalloid solution at constant flow. Isoproterenol infusion (10 nM) produced increases in heart rate, left ventricular systolic pressure, rate of pressure development, myocardial oxygen consumption and adenosine and inosine concentrations of venous effluent and surface exudate and produced decreases in coronary vascular resistance. The presence of the adenosine receptor antagonist, 8-(4-sulfophenyl) theophylline (spT) (100 microM), in the perfusate had little or no effect upon most of the responses to isoproterenol except that it significantly enhanced the isoproterenol-induced increases in adenosine release and adenosine concentrations in the venous effluent and surface exudate. The isoproterenol-induced change in adenosine concentration per unit change in oxygen consumption was approximately 3-fold greater in the presence of spT than in its absence. This extra adenosine production may tend to overcome the competitive blocking effect of spT and help explain why agents such as spT are not always effective in blocking metabolic vasodilation.[Abstract] [Full Text] [Related] [New Search]